Nucleai
Nucleai uses artificial intelligence to map where different cells sit within tumour tissue samples, helping drug companies understand who responds to a treatment and why.
Overview
Nucleai, headquartered in Tel Aviv, provides an AI-powered spatial tissue analysis platform for oncology drug development. It integrates multimodal tissue imaging (H&E, immunohistochemistry, multiplex immunofluorescence and spatial transcriptomics) with clinical outcome data to derive explainable spatial biomarkers. The company reports work with more than 12 of the top 20 biopharma companies across 30 or more clinical trials, and holds ISO 27001 and ISO 13485 certification. Recent collaborations include a large-scale antibody-drug conjugate (ADC) programme with Gilead Sciences examining why target-positive tumours resist ADCs (2026), an integrated spatial proteomics offering with Sirona Dx and an expanded partnership with the University of Glasgow. Investors named on the website include Section32, Sanofi, M Ventures and Debiopharm; no financing round is disclosed.
Notes
top- nucleai.com is now a parked domain; the live site is nucleai.ai. Funding rounds (including a reported 2022 Series B) could not be sourced from primary releases so none are recorded. Founding year not sourced.
Pages like this
not linked directly; found by shared links- IdeaStandards for spatial and multiplex tissue biomarkers before they reach the clinic
Shares Single-cell & spatial profiling, Digital pathology & AI.
- IdeaMap which tumour clones sit next to which immune cells before choosing therapy
Shares Single-cell & spatial profiling, Digital pathology & AI.
- IdeaClear the suppressive neutrophils out of pancreatic tumours first
Shares Single-cell & spatial profiling, Digital pathology & AI.
- IdeaMatch therapy to the type of scar-forming cell in the tumour
Shares Single-cell & spatial profiling, Digital pathology & AI.
- TechnologySpatial-omics-guided treatment selection
Shares Single-cell & spatial profiling, Digital pathology & AI.
- IdeaTurn the map of immune cells inside a tumour into a standardised test
Shares Single-cell & spatial profiling, Digital pathology & AI.